Monkey pox in Italy and Europe
Monkey pox in Italy and Europe
ENABLE UPDATES
Across Europe, 10,604 cases of varicella, Also known as varicella: is what emerges from the latest update released today byEcdcthe European Center for Disease Prevention and Control, which has also developed a map report countries more or less at risk, as was also the case with Covid.
According to what was released today by the European Center, as of July 19th, Italy appears in full color with redthat is, it recorded between 100 and 499 cases, precisely they are in our country 374while in dark red, with more than 500 reported cases, there are Spain, Portugal, France AND Germany, respectively with 2,835, 515, 912 and 2,033 cases, along with the Netherlands (656). the bad too UK where the confirmed infections, according to the official resources of the 36 countries of the European region, are 2115.
According to the ECDC, most cases identified in Europe have a average age 31 to 40 years (42%) and are male (99.5%). Among the cases with HIV known, 38% were positive. About the symptomsthe most common are skin rashes (94.5%) and systemic ones, that is, fever, fatigue, muscle pain, vomiting, diarrhea, chills, sore throat or headache (65%).
Of the more than 10,000 reported cases, 256 were hospitalized in hospital (8.1%), of which 114 cases required clinical care. Only one case was admitted to intensive care. They don’t register at the moment deaths. Among those infected, 31 were reported as health workers, but no occupational exposures were reported.
Meanwhile, in Italy, the Ministry of Health authorized the temporary marketing of Jyneos vaccine produced by the Nordic company of Bavaria against monkeypox.
The provision indicates the consent of the Technical-Scientific Commission of the Italian Medicines Agency which “assessed the available documentation and examined what was transmitted by the Ministry of Health in relation to the Jynneos vaccine (modified non-replicating live Ankara vaccine virus), believes that this The last one, already authorized by the FDA for the prevention of smallpox in adult individuals with high risk of infection, is suitable for the recognition of the temporary and extraordinary authorization provided for in article 5, § 2, of legislative decree No. 219/2006, awaiting the availability of a vaccine with the same indication approved by the EMA”.
Source: Fan Page IT
Smith Charles is a talented entertainment journalist and author at The Nation View. He has a passion for all things entertainment and writes about the latest movies, TV shows, music, and celebrity news. He’s known for his in-depth interviews with actors, musicians, and other industry figures, and his ability to provide unique perspectives on the entertainment industry.
